Akebia Therapeutics vs Amarin
AKBA and AMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and AMRN compare
Amarin is the larger company, worth 38 times as much as Akebia Therapeutics ($5.0B against $131M).
Akebia Therapeutics grew revenue faster over the last twelve months (−12.4% versus −22.3% for Amarin).
Amarin keeps more of each dollar of sales as profit, with a net margin of −10.9% compared with −22.6% at Akebia Therapeutics.
Amarin scores higher on the StockData Score (10 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | AMRN |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $5.0B |
| Share price | $0.474 | $11.38 |
| Change, 1 year | −74.4% | −29.8% |
| Change, 5 years | −82.9% | −85.4% |
| Beta (5Y) | 1.10 | 1.54 |
| Employees | 194 | 80 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 28.6× |
| P/B | 6.5× (better) | 11.3× |
| P/FCF | 9.5× | – |
| FCF yield | 10.5% | – |
| Fair value | – | $7.00 |
| Margin of safety | – | −62.5% |
| Growth | ||
| Revenue growth (TTM) | −12.4% (better) | −22.3% |
| Revenue growth, 5Y average | −4.3% (better) | −19.0% |
| Profitability | ||
| Gross margin | 78.9% (better) | 40.9% |
| Operating margin | −15.7% (better) | −18.2% |
| Net margin | −22.6% | −10.9% (better) |
| FCF margin | 7.0% | – |
| Return on equity | −144% | −4.2% (better) |
| Return on invested capital | – | −17.3% |
| Financial health | ||
| Debt / equity | 2.47 (better) | 0.00 |
| Current ratio | 1.36 | 3.50 (better) |
| Altman Z-score | −6.30 | 13.05 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 1.0% |
| Held by insiders | 2.9% | 7.0% |
| Insider net buying, 12 months | −$876K | – |
| Short interest, % of float | 10.1% | – |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- AMRN stock overview
- AMRN income statement
- AMRN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.